

UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NA	MED APPLICANT	- (4) -	ATTORNE	Y DOCKET NO.
033,234	04/25/79	Valentino J.	St∈lla, et	al.,	NHSRX	352A
Norman H. St Burns, Doane, George Mason Washington a Arlington Va	Swecker & Building nd Prince		MAIL	Far ART UNI 121 E MAILED	T PAI	PER NUMBER
		in charge of your application.	FED D.	980		
Part I THE FOLLO 1. Notice of Re 3. Notice of Inf Part II SUMMARY	period for response to the period formal Patent Application.	ation, Form PTO-152.	three month(s), on to become abandor ACTION: 2. Notice of Inf	7 80 day ned. 35 U.S	s from the date .C. 133	, 8.
1. Claims	24-3	<u>0</u>			_ are pending i	n the application.
Of the above	, claims				_ are withdraw	n from consideration
2. Claims					_ have been car	ncelled.
. 3. Claims	, , , , , , , , , , , , , , , , , , , 				_ are allowed.	
4. V Claims	24-	30			_ are rejected.	
5. Claims					_ are objected t	to.
. 6. Claims				are subject to	restriction or	election requiremen
<u>ت</u>						
8. The drawing	correction request f	iled on		has been	approved.	disapproved.
9.	_	claim for priority under 35 U. een receivedbeen filed filed or	in parent application			
-		be in condition for allowance Ex parte Quayle, 1935 C.D. 1		tters, prosecutio	n as to the mer	its is closed in ac-

Serial No. 033,234 Art Unit 121

Claims 24,27 and 29 are rejected under 35 USC 103 as being obvious over German Offenlegungsschrift 2,064,474 and the French patent 1,093,728 considered together for reasons In traversing the rejections, applicants place of record. great emphasis on the differences in the properties disclosed in the art and in applicants' specification. However, it is not believed that the differences in phosphoric acid or ester group would effect the properties of the claimed compounds since the anticonvulsant or antiarrythmic activity is due to the presence of 5,5-diphenyl-hydantoin nucleus. Thus, in order to rebut this prima facie case of obviousness, actual differences in fact of an unexpected nature must be shown since compounds which are very similar in structures would be expected to have similar properties. In re Hoch, 166 USPQ 406.

Claims 25 to 29 are rejected under 35 USC 132 as being drawn to new matter and 35 USC 112, paragraph 1. The claims encompass new subgeneric concepts which are not disclosed anywhere in the specification. The discription of only one compound, 3-phosphoryloxymethyl-diphenylhydantoin (page 7) is not sufficient to implicitly or explicitly support the new subgeneric groups of compounds encompassed by the claims. Thus the claims are drawn to new matter.

Claim 30 is rejected under 35 USC 112, paragraph 2.

The claim is improper since it depends on a cancelled claim.

Serial No. 033,234 Art Unit 121

Furthermore, the position of the two phenyl groups should be specified.

Claims 24 to 30 are rejected. The rejection is made FINAL.

JTFan/jlb

A/C 703

557-2517

02/05/80

JOHN M. FORD
EXAMINER
GROUP ART UNIT 121